A detailed history of Gallacher Capital Management LLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Gallacher Capital Management LLC holds 7,166 shares of HALO stock, worth $362,527. This represents 0.2% of its overall portfolio holdings.

Number of Shares
7,166
Previous 9,244 22.48%
Holding current value
$362,527
Previous $376 Million 0.22%
% of portfolio
0.2%
Previous 0.19%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 06, 2024

SELL
$37.81 - $52.4 $78,569 - $108,887
-2,078 Reduced 22.48%
7,166 $375 Million
Q1 2024

May 06, 2024

SELL
$33.68 - $41.95 $72,715 - $90,570
-2,159 Reduced 18.93%
9,244 $376 Million
Q4 2023

Feb 06, 2024

BUY
$33.32 - $42.1 $174,763 - $220,814
5,245 Added 85.17%
11,403 $421 Million
Q3 2023

Nov 13, 2023

BUY
$36.46 - $44.03 $224,520 - $271,136
6,158 New
6,158 $235 Million

Others Institutions Holding HALO

About HALOZYME THERAPEUTICS, INC.


  • Ticker HALO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 139,288,992
  • Market Cap $7.05B
  • Description
  • Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...
More about HALO
Track This Portfolio

Track Gallacher Capital Management LLC Portfolio

Follow Gallacher Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gallacher Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gallacher Capital Management LLC with notifications on news.